(TEVA)—XENE -20% on phase-2 failure in PHN: https://finance.yahoo.com/news/teva-xenon-announce-phase-ii-121500466.html TV-45070 did not meet the primary endpoint of a statistically significant change in pain from baseline to week four as assessed by the numeric rating scale (NRS). Secondary endpoints were also not met.